BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25701283)

  • 1. An analysis of FDA-approved drugs for inflammation and autoimmune diseases.
    Kinch MS; Merkel J
    Drug Discov Today; 2015 Aug; 20(8):920-3. PubMed ID: 25701283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in pharmaceutical targeting of clinical indications: 1930-2013.
    Kinch MS; Merkel J; Umlauf S
    Drug Discov Today; 2014 Nov; 19(11):1682-1685. PubMed ID: 24881779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2017 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2018 Aug; 23(8):1469-1473. PubMed ID: 29751111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of FDA-approved drugs for neurological disorders.
    Kinch MS
    Drug Discov Today; 2015 Sep; 20(9):1040-3. PubMed ID: 25681791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target selection for FDA-approved medicines.
    Kinch MS; Hoyer D; Patridge E; Plummer M
    Drug Discov Today; 2015 Jul; 20(7):784-9. PubMed ID: 25462532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of FDA-approved new molecular entities: 1827-2013.
    Kinch MS; Haynesworth A; Kinch SL; Hoyer D
    Drug Discov Today; 2014 Aug; 19(8):1033-9. PubMed ID: 24680947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of FDA-approved drugs for infectious disease: antibacterial agents.
    Kinch MS; Patridge E; Plummer M; Hoyer D
    Drug Discov Today; 2014 Sep; 19(9):1283-7. PubMed ID: 25043770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of FDA-approved drugs for metabolic diseases.
    Kinch MS; Umlauf S; Plummer M
    Drug Discov Today; 2015 Jun; 20(6):648-51. PubMed ID: 25680688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2020 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2021 Dec; 26(12):2794-2799. PubMed ID: 34252611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.
    Christopoulos PF; Gjølberg TT; Krüger S; Haraldsen G; Andersen JT; Sundlisæter E
    Front Immunol; 2021; 12():668207. PubMed ID: 33912195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of FDA-approved drugs for oncology.
    Kinch MS
    Drug Discov Today; 2014 Dec; 19(12):1831-5. PubMed ID: 25172803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of innovation: an assessment of intellectual property.
    Kinch MS; Raffo J
    Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.